ClinicalTrials.gg
RecruitingNCT05329584iAccelerateUpdated May 29, 2025

InSpace Accelerated Rehabilitation Study

An interventional study of InSpace Subacromial Tissue Spacer in Rotator Cuff Tears, sponsored by Stryker Endoscopy. Recruiting at 11 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by Stryker Endoscopy (part of Stryker) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Rotator Cuff Injuries by Stryker — 2 open to participants now, 3 under way, none of them phase 3. Rotator Cuff Injuries · Stryker.

Started
2022
the only one that year
No phase
9 of 12
1 open now
Registered
10th of 12
by date

Among the 12 studies in Rotator Cuff Injuries by Stryker, this one is the only one that started in 2022, is one of 9 with no phase, and was the 10th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

2 of the 12 studies in Rotator Cuff Injuries by Stryker are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Rotator Cuff Injuries by Stryker, or all of them as a file.
02

Study summary

This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.

Read the detailed description

Study Objectives:

Primary:

  • To evaluate clinical outcomes of both a formalized or an at-home rehabilitation program when used in conjunction with the InSpace device as compared to the corresponding InSpace Pivotal study results.
  • To demonstrate consistency of each intervention group with the corresponding historical control study results.
  • To demonstrate that comparable clinical outcomes can be achieved for each intervention group.

Secondary:

  • Change in clinical outcomes compared to baseline.
03

Conditions studied

  • Rotator Cuff Tears

Browse trials for

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects MUST meet ALL the following criteria to be included in the study:

  • The subject has signed the IRB approved Form (ICF) specific to this study prior to enrollment
  • Is male or female ≥ sixty-five (65) years of age
  • Positive diagnostic imaging by MRI within 9 months of enrollment of the index shoulder indicating a full thickness MRCT:

    • Measuring ≥ 5 cm in diameter
    • Involving ≥ two tendons
  • Functional deltoid muscle and preserved passive range of motion on physical examination
  • Documented VAS score > 30 mm pain
  • Failed non-operative treatment of at least 3 months from the initial treatment to include one or more of the following:

    • Oral analgesics
    • Anti-inflammatory medication (e.g., ibuprofen, naproxen)
    • injection(s)
    • Physical therapy
    • Activity modification
    • Rest (sling used)
  • Must be able to read and understand the approved Informed Consent Form (written and oral)
  • Must be in general good health (as determined by the Investigator) based on screening assessments and medical history
  • Must be independent, ambulatory, and can comply with all post-operative evaluations, visits, and electronic database collection

Intra-operative Inclusion Criteria

Subjects MUST meet the following criteria to be randomized in the study:

  • Full thickness tear
  • Tear size ≥ 5 cm in diameter
  • Tear involving ≥ two tendons

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study, if they meet ANY of the following individual exclusion criteria:

  • Known allergy to the device material (copolymer of PLA (poly (lactic acid) and -ε-caprolactone)
  • Evidence of the following conditions:

    • Severe gleno-humeral or acromio-humeral arthritis
    • Full thickness cartilage loss as seen on MRI
    • History within the past 5 years of anterior or posterior shoulder subluxation or dislocation as determined by history, examination, or radiographic findings
    • Pre-existing deltoid defect or deltoid palsy
    • Major joint trauma, infection, or necrosis
    • Partial thickness tears of the supraspinatus
    • Fully reparable rotator cuff tear [Tear of less than 5 cm in diameter (or \< 4 cm2) with retractable tendon that can be fully repaired]
    • Known neurovascular compromise
    • Complete deltoid muscle palsy
    • Traumatic muscle tears of the pectoralis or deltoid
  • The subject requires concomitant:

    • Subscapularis repair
    • Labral repair of any type
    • Biceps tenodesis
  • Previous surgery of the index shoulder in the past 1 year, excluding diagnostic arthroscopy
  • The subject's condition is bilateral and rotator cuff repair is scheduled or to be scheduled over the course of this study for the contra lateral shoulder
  • Major medical condition that could affect quality of life and influence the results of the study (e.g., rheumatoid arthritis)
  • The subject has documented evidence of a history (e.g., liver testing) of drug/alcohol abuse within 12 months of enrollment
  • The subject's condition represents a worker's compensation case
  • The subject is currently involved in a health-related litigation procedure
  • Females of who are pregnant or plan to become pregnant.
  • Concurrent participation in an clinical study one month prior to enrollment or during the entire study period
  • The subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.), to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant to follow-up
  • The subject is receiving prescription narcotic pain medication for conditions unrelated to the index shoulder condition
  • The subject currently has an acute infection in the area surrounding the surgical site.
  • Baseline WORC score less than 420

Intra-operative Exclusion Criteria:

Subjects will not be randomized and will be terminated from the study if they meet ANY of the following individual intra-operative exclusion criteria:

  • Rotator cuff is/presents with:

    • Fully reparable with adequate tissue and muscle quality (equivalent to Goutallier stage 1 or 2)
    • Partial thickness tear of the supraspinatus
    • Evidence of significant osteoarthritis
  • The subject requires concomitant:

    • Subscapularis repair
    • Labral repair of any type
    • Biceps tenodesis
  • Coracoacromial ligament functional deficiency or shoulder instability is identified
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Group I

    InSpace device + accelerated rehabilitation in a formalized program (FP)

    Device: InSpace Subacromial Tissue Spacer

  • Experimental
    Group II

    InSpace device + accelerated rehabilitation in an at-home program (AHP)

    Device: InSpace Subacromial Tissue Spacer

Interventions

  • DeviceInSpace Subacromial Tissue Spacer

    Rotator Cuff Tear Treatment

06

What researchers measure

Primary outcomes

  1. Change in American Shoulder and Elbow (ASES) Score

    This is a subject self-report questionnaire and Investigator assessment questionnaire. The subject portion collects information on activities of daily living (i.e., 10 questions). The Investigator assessment portion documents ROM (forward elevation/flexion, external rotation, internal rotation, cross-body adduction), signs, strength, and instability. ASES minimal clinical important difference (MCID) and substantial clinical benefit (SCB) have been previously described for the ASES score in patients undergoing rotator cuff repair as 11.1 and 17.5, respectively. Change in American Shoulder and Elbow Surgeons (ASES) Score will be expressed as the percentages demonstrating a minimal clinical important difference (MCID; ASES ≥ 11.1) and the substantial clinical benefit (SCB; ASES ≥ 17.5) in ASES from baseline at Month 12. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome).

    Time frame: Day 0 through Month 12

Secondary outcomes

  1. Safety Assessment

    • Safety will be evaluated by type, frequency, severity, and relatedness of adverse events to study intervention at each follow-up visit through Month 24

    Time frame: Day 0 through Month 24

  2. Change in Western Ontario Rotator Cuff (WORC) Score

    Change in WORC Score from baseline. Minimum value: 2,100, Maximum value: 0 (with a lower score indicating a better outcome). This is a subject self-report questionnaire that is a disease-specific Quality of Life Measurement Tool specifically designed to evaluate quality of life in persons with pathology of the rotator cuff. It is comprised of 21 items in 5 domains (i.e., physical symptoms, sports and recreation, work, lifestyle, emotions).

    Time frame: Day 0 through Month 24

  3. Change in Constant Score (CS) Outcome Score

    Change in CS Outcome Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a self-reported questions as well as Investigator or designee performed assessment of the shoulder. The tool is divided into four subscales: pain, activities of daily living, strength and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder.

    Time frame: Day 0 through Month 24

  4. Change in EuroQol 5-Dimensions Questionnaire (EQ-5D-5L) Score

    Change in EQ-5D-5L Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a subject self-report questionnaire to measure health-related quality of life (HRQOL). It consists of 5 questions capturing the subject's current health across five dimensions (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). It also includes a numerical visual analogue scale (EQ-VAS).

    Time frame: Day 0 through Month 24

  5. Change in Visual Analog Scale (VAS) Score

    Change in VAS Score from baseline. This is a subject self-report questionnaire to measure pain. The patient marks on the line the point that they feel represents their perception of their current state. The amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain. (An extreme amount of pain would be considered a worse outcome)

    Time frame: Day 0 through Month 24

  6. Change in Range of Motion (ROM) Score

    Change in ROM Score from baseline. Minimum value: 0, Maximum value: 180 (with a higher score indicating a better outcome).

    Time frame: Day 0 through Month 24

  7. Change in Single Assessment Numeric Evaluation (SANE) Score

    Change in SANE from baseline. Minimum value: 0%, Maximum value: 100% (with 100% being normal). This is a subject self-report questionnaire to measure function. The patient marks on the line the point that they feel represents their perception of their current state of functional improvement. Example: "How would you rate your affected shoulder today as a percentage of normal (0% to 100% scale with 100% being normal)?"

    Time frame: Day 0 through Month 24

  8. Patient's satisfaction with their procedure

    Patient Satisfaction Score at Month 12 and Month 24. This is a single-question to evaluate the patients' current state of satisfaction. Responses are binary with Yes or No answers. ('Yes' would be considered a positive outcome)

    Time frame: Month 12 and Month 24

  9. Costing

    Costs associated with all visits

    Time frame: Day 0 through Month 24

  10. Time to Recovery

    Time to recovery by cumulative time between discharge and return to driving

    Time frame: Day 0 through Month 24

  11. Analgesia Use

    Analgesia use (drug and frequency)

    Time frame: Day 0 through Month 24

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Apr 2026, 50 months after the start.

Of 252 interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2022
First posted
Apr 15, 2022
StartActual
Feb 7, 2022
Primary completionEst.
Apr 2026
CompletionEst.
Dec 2026
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05329584
Lead sponsor
Stryker Endoscopy
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Feb 7, 2022
Primary completion
Apr 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 29, 2025

Study contacts

Hayley Taylor, MS
Contact
hayley.taylor@stryker.com
805-705-4206
Colleen Roden, MS
study director · Stryker Endoscopy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion